PD65-10 USING MP-MRI GUIDED PROSTATE NEEDLE BIOPSY SAMPLES TO IMPROVE PROSTATE CANCER DIAGNOSIS.

Abstract

You have accessJournal of UrologyProstate Cancer: Markers II1 Apr 2017PD65-10 USING MP-MRI GUIDED PROSTATE NEEDLE BIOPSY SAMPLES TO IMPROVE PROSTATE CANCER DIAGNOSIS. Jonathan OLIVIER, Jonathan Kay, Vasili Stravinides, Freeman Alex, Hashim Ahmed, Caroline Moore, Emberton Mark, and Whitaker Hayley Jonathan OLIVIERJonathan OLIVIER More articles by this author , Jonathan KayJonathan Kay More articles by this author , Vasili StravinidesVasili Stravinides More articles by this author , Freeman AlexFreeman Alex More articles by this author , Hashim AhmedHashim Ahmed More articles by this author , Caroline MooreCaroline Moore More articles by this author , Emberton MarkEmberton Mark More articles by this author , and Whitaker HayleyWhitaker Hayley More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.2960AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Prostate cancer is a heterogeneous disease both in terms of clinical presentation and pathology which can lead to very different clinical outcomes. Conventional prognostic factors, including serum PSA levels, Gleason score and pathological stage are often inaccurate and histological biomarkers could be useful in distinguishing indolent from aggressive prostate cancers. Tissue microarrays (TMAs) are useful for validating protein biomarker expression in large cohorts of patient samples using immunohistochemistry (IHC) but are often created from radical prostatectomy specimens which do not accurately represent diagnostic biopsies. The limited tumour availability in biopsy samples has led us to develop an improved method for constructing TMAs to study multiple biomarkers simultaneously on biopsy tissues. Objectives: Validate a new method of constructing TMA blocks from prostate needle biopsies and study the link between well known biomarkers (PSA, PSMA, p63,MSMB and AMACR) and mp-MRI data METHODS Patients attending UCLH with suspected prostate cancer were recruited to the PICTURE study and underwent a diagnostic mp-MRI scan and subsequent image-guided biopsy. This was analysed by a pathologist to confirm tumour Grade. Clinical and MRI data were routinely collected. We extracted the regions of tumour within biopsy samples and re-embedded them so that they could easily be repositioned into a recipient TMA block. Blocks were sectioned and stained using automated IHC for established prostate cancer biomarkers including p63, AMACR, PSMA, MSMB and PSA. RESULTS We have successfully produced TMA blocks containing representative regions of benign and tumour samples for 200 patients. 99.4% of the cores included were recovered in the TMAs slides. Biomarker expression correlates with Grade of cancer for PSA (p=0.01), MSMB (p=0.016) p63 (p<0.0001), AMACR (p<0.0001) and PSMA (p<0.0001). Expression also correlates with Likert score for PSMA (p=0.009), p63 (p=0.023) and AMACR (p<0.0001). CONCLUSIONS This new method of constructing TMA blocks is effective at utilising interesting regions of biopsy tissue. It allows multiple biomarkers to be assessed quickly from large cohort studies that accurately represent the tissue routinely used for diagnosis. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e1270 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Jonathan OLIVIER More articles by this author Jonathan Kay More articles by this author Vasili Stravinides More articles by this author Freeman Alex More articles by this author Hashim Ahmed More articles by this author Caroline Moore More articles by this author Emberton Mark More articles by this author Whitaker Hayley More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...